DSM Integrated Annual Report 2020

8 Intangible assets

 

 

Goodwill

 

Licenses and patents

 

Under construction

 

Development projects

 

Other

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 1 January 2019

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

1,927

 

206

 

50

 

296

 

1,776

 

4,255

Amortization and impairment losses

 

18

 

99

 

-

 

43

 

1,005

 

1,165

Carrying amount

 

1,909

 

107

 

50

 

253

 

771

 

3,090

 

 

 

 

 

 

 

 

 

 

 

 

 

Changes in carrying amount:

 

 

 

 

 

 

 

 

 

 

 

 

- Capital expenditure

 

-

 

1

 

50

 

51

 

8

 

110

- Put into operation

 

-

 

4

 

(26)

 

-

 

22

 

-

- Acquisitions

 

338

 

1

 

-

 

-

 

124

 

463

- Amortization

 

-

 

(13)

 

-

 

(26)

 

(136)

 

(175)

- Impairment losses

 

-

 

(2)

 

-

 

(21)

 

(8)

 

(31)

- Exchange differences

 

36

 

2

 

1

 

4

 

12

 

55

- Other reclassifications

 

-

 

-

 

(4)

 

6

 

1

 

3

 

 

374

 

(7)

 

21

 

14

 

23

 

425

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 31 December 2019

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

2,301

 

216

 

71

 

338

 

1,966

 

4,892

Amortization and impairment losses

 

18

 

116

 

-

 

71

 

1,172

 

1,377

Carrying amount

 

2,283

 

100

 

71

 

267

 

794

 

3,515

 

 

 

 

 

 

 

 

 

 

 

 

 

Changes in carrying amount:

 

 

 

 

 

 

 

 

 

 

 

 

- Capital expenditure

 

-

 

1

 

77

 

42

 

43

 

163

- Put into operation

 

-

 

11

 

(59)

 

-

 

48

 

-

- Acquisitions

 

777

 

3

 

36

 

34

 

837

 

1,687

- Amortization

 

-

 

(13)

 

-

 

(35)

 

(152)

 

(200)

- Impairment losses

 

(20)

 

(14)

 

-

 

(74)

 

(2)

 

(110)

- Exchange differences

 

(138)

 

(2)

 

-

 

-

 

(28)

 

(168)

- Reclassification to held for sale

 

(387)

 

(3)

 

(1)

 

(28)

 

(18)

 

(437)

- Other

 

-

 

(2)

 

(9)

 

17

 

(1)

 

5

 

 

232

 

(19)

 

44

 

(44)

 

727

 

940

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 31 December 2020

 

 

 

 

 

 

 

 

 

 

 

 

Cost

 

2,535

 

202

 

115

 

380

 

2,621

 

5,853

Amortization and impairment losses

 

20

 

121

 

-

 

157

 

1,100

 

1,398

Carrying amount

 

2,515

 

81

 

115

 

223

 

1,521

 

4,455

The amortization of intangible assets is included in Cost of sales, Marketing & Sales, Research & Development and General & Administrative expenses.

Over the past few years, DSM has acquired several entities in business combinations that have been accounted for by the acquisition method, resulting in recognition of goodwill and other intangible assets. The amounts assigned to the acquired assets and liabilities are based on assumptions and estimates about their fair values. In making these estimates, management consults independent, qualified appraisers if appropriate.

The impairment losses in 2020 are €110 million. This includes a €67 million impairment of mainly intangible assets previously reported in the Innovation segment relating to DSM Bio-based Products & Services, owing to an expected subdued market outlook for biofuels which led to insufficient expected future cash flows. Consequently, the recoverable amount is measured at fair value minus costs of disposal, which was assessed to be of immaterial value to DSM. Furthermore, the impairment losses include the impairment of €38 million relating to DSM Advanced Solar on its solar assets previously reported in the Innovation segment, following the sale of the solar coating activities to Covestro AG. This led to insufficient expected future cash flows for the remaining solar assets, primarily consisting of goodwill and technology. Therefore, the recoverable amount for these assets is measured at fair value minus costs of disposal, which is assessed to be of immaterial value to DSM.

The breakdown of the carrying amount of goodwill at year-end 2020 is as follows.

Goodwill per acquisition

Acquisition

 

2020

 

2019

 

Cash generating unit

 

Functional Currency

 

Year of acquisition

 

 

 

 

 

 

 

 

 

 

 

Erber Group1

 

521

 

-

 

DSM Nutritional Products

 

EUR

 

2020

Martek

 

378

 

413

 

DSM Nutritional Products

 

USD

 

2011

Glycom1

 

341

 

-

 

DSM Nutritional Products

 

DKK

 

2020

Fortitech

 

283

 

310

 

DSM Nutritional Products

 

USD

 

2012

Ocean Nutrition Canada

 

190

 

204

 

DSM Nutritional Products

 

CAD

 

2012

Kensey Nash

 

132

 

144

 

DSM Biomedical

 

USD

 

2012

Andre Pectin

 

131

 

135

 

DSM Food Specialties

 

CNY

 

2019

Tortuga

 

62

 

89

 

DSM Nutritional Products

 

BRL

 

2013

Royal CSK

 

26

 

114

 

DSM Food Specialties

 

EUR

 

2019

NeoResins2

 

-

 

358

 

DSM Resins & Functional Materials

 

EUR

 

2005

Other acquisitions2

 

451

 

516

 

 

 

 

 

 

Total

 

2,515

 

2,283

 

 

 

 

 

 

1

Based on provisional PPA, see Note 3 Change in the scope of consolidation.

2

As per 31 December 2020, goodwill has been reclassified to assets held for sale for an amount of €387 million (NeoResins €358 million, Other acquisitions €29 million), see Note 3 Change in the scope of consolidation.

Goodwill per Cash generating unit

Cash generating unit

 

2020

 

2019

 

 

 

 

 

DSM Nutritional Products

 

2,0181

 

1,2601

DSM Food Specialties

 

227

 

321

DSM Biomedical

 

203

 

222

DSM Protective Materials

 

40

 

42

DSM Engineering Materials

 

27

 

29

DSM Resins & Functional Materials2

 

-

 

384

DSM Advanced Solar

 

-

 

16

DSM Bio-based Products & Services

 

-

 

9

Total

 

2,515

 

2,283

1

Contains provisional PPA, see Note 3 Change in the scope of the consolidation.

2

As per 31 December 2020, goodwill has been reclassified to assets held for sale for an amount of €387 million, Note 3 Change in the scope of the consolidation.

The annual impairment tests of goodwill are performed in the fourth quarter. The recoverable amount of the Cash generating units (CGUs), except for the previously mentioned CGUs DSM Bio-based Products & Services and DSM Advanced Solar, is based on a value-in-use calculation. DSM Nutritional Products is the CGU to which a significant amount of (provisional) goodwill is allocated. In 2020 goodwill from DSM Hydrocolloids (DHC) was re-allocated to DSM Food Specialties due to further integration of the organization. The comparative figures have been adjusted accordingly.

The cash flow projections are derived from DSM’s business plan (Corporate Strategy Dialogue) as adopted by the Managing Board and updated on a yearly basis. Mature businesses come to a terminal value after five years. The terminal value growth rate is determined with the assumption of limited inflationary growth. For emerging businesses, an explicit forecast period of ten years is used with the same assumption for growth in the terminal value. The key assumptions in the cash flow projections relate to the market growth for the CGUs and the related revenue projections, EBITDA developments, and the rates used for discounting cash flows.

Key assumptions for goodwill impairment tests

 

 

2020

 

2019

 

 

 

 

 

Forecast period (years)

 

 

 

 

- Mature business

 

5

 

5

- Emerging business

 

10

 

10

 

 

 

 

 

Terminal value growth

 

1%

 

1%

 

 

 

 

 

Pre-tax discount rate

 

 

 

 

- DSM Nutritional Products

 

9.1%

 

8.1%

 

 

 

 

 

Organic sales growth

 

 

 

 

DSM Nutritional Products

 

 

 

 

- Year 1–5

 

4 – 7%

 

2 – 6%

For DSM Nutritional Products the growth assumptions are based on the growth of the global food and feed markets. A sensitivity test was performed on the impairment tests of the CGUs and showed that the conclusions of these tests would not have been different if reasonable possible adverse change in key parameters had been assumed.

The market capitalization of DSM at 31 December 2020 amounted to €25,545 million (31 December 2019: €21,063 million) and was clearly above the carrying amount of net assets, thus providing an additional indication that goodwill was not impaired.

Development costs

The carrying amount of development costs at 31 December 2020 included €136 million (2019: €125 million) mainly relating to strategic projects which are not being amortized yet. The recoverable amount of these CGUs was estimated based on the present value of the future cash flows expected to be derived from the CGUs (value-in-use).

Other intangible assets

 

 

2020

 

2019

 

 

Cost

 

Amortization

 

Carrying amount

 

Of which acquisition- related

 

Of which acquisition- related

 

 

 

 

 

 

 

 

 

 

 

Application software

 

315

 

(217)

 

98

 

62

 

2

Marketing-related

 

111

 

(41)

 

70

 

70

 

81

Customer-related

 

1,001

 

(381)

 

620

 

620

 

311

Technology-based

 

626

 

(174)

 

452

 

429

 

89

Drawing rights

 

244

 

(88)

 

156

 

-

 

-

Other

 

324

 

(199)

 

125

 

109

 

63

Total

 

2,621

 

(1,100)

 

1,521

 

1,290

 

546

 

 

 

 

 

 

 

 

 

 

 

Total 2019

 

1,966

 

(1,172)

 

794

 

546

 

 

Other intangible assets include (partially provisional) customer relationships, which were obtained during the acquisition of Erber Group and Glycom in 2020, as well as CSK in 2019 and Fortitech in 2012. Technology-based intangibles were mainly obtained via the acquisition of Erber Group and Glycom in 2020 and CSK in 2019. Intangible assets are included in the annual goodwill impairment test as discussed in this section; they are amortized on a straight-line basis. There are no intangible assets with an indefinite useful life (same as in 2019). The acquisition-related numbers 2019 have been adjusted for comparison reasons.

Other intangible assets also include drawing rights contracts with Fibrant. Fibrant will continue to supply at least 80% of DSM Engineering Materials’ caprolactam needs in Europe and North America for 15 years (2015–2030) via a drawing rights contract, effectively maintaining DSM Engineering Materials’ backward integration. Initially the fair value of this contract has been recognized as an intangible asset by DSM Engineering Materials; for subsequent measurement, the initial fair value is the deemed cost of the asset, which is subject to straight-line amortization. At the end of 2020, it had a carrying amount of €156 million (2019: €167 million), a remaining useful life of 10 years, and an amount of €39 million was still payable to Fibrant for the acquisition of the drawing rights (2019: €44 million).

CGU
Cash Generating Unit
Earnings before interest, tax, depreciation and amortization (EBITDA)
EBITDA is the sum of operating profit plus depreciation and amortization. Adjusted EBITDA is the EBITDA adjusted for material items of profit or loss coming from acquisitions/divestments, restructuring and other circumstances that management deem it necessary to adjust in order to provide clear reporting on the development of the business.